Precision Medicine

Precision Medicine Approach Helps Identify and Treat Toddler’s Rare Disease

Newswise — NEW YORK, NY (October 22, 2015) — A 20-month-old girl suffering from a rare neurodegenerative disease was diagnosed by exome sequencing and successfully treated. The case, which exemplifies the potential of precision medicine, involved scientists at Columbia University Medical Center (CUMC) and Duke University, and is described in …

Read More »

NeoGenomics to Acquire Clarient for $275 Million

FORT MYERS, Fla., Oct. 21, 2015 /PRNewswire/ — NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has reached an agreement to acquire Clarient, Inc., and its wholly-owned subsidiary Clarient Diagnostic Services, Inc., a provider of comprehensive cancer diagnostic testing to hospitals, physicians …

Read More »

Metamark’s Novel Prognostic Test Demonstrates Potential to be Cost-Effective for Management of Prostate Cancer

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Metamark Genetics, Inc. (“Metamark” or the “Company”), a leader in commercializing high-value urologic oncology products, today announced that a study published in The Oncologist demonstrates that use of its novel proteomic prognostic test ProMark®, for early-stage prostate cancer, is likely to result in more cost-effective care than the National …

Read More »

Opko Health and Vanderbilt Collaborate on Genomics Testing

MIAMI–(BUSINESS WIRE)–OPKO Health, Inc. (NYSE:OPK) announced today a collaboration among its subsidiary, BioReference Laboratories, Inc., the Department of Pathology, Microbiology, and Immunology and the Vanderbilt-Ingram Cancer Center (VICC) at Vanderbilt University Medical Center (VUMC) to leverage large scale genomics testing for optimal cancer care. Each of the organizations has committed …

Read More »

Quest Diagnostics Presents Study Demonstrating Clinical Value in Genetic Tests for Predicting Disease

MADISON, N.J., Oct. 8, 2015 /PRNewswire/ — Genetic testing for mutations beyond those currently recommended in medical guidelines may aid the identification of more couples at risk of having a child with cystic fibrosis, according to a study presented today at the 2015 American Society of Human Genetics (ASHG) Annual Meeting, which runs …

Read More »

Claritas Clinical Exome Delivers Whole-Exome Test Results within 4 Weeks

BOSTON, Oct. 7, 2015 /PRNewswire/ — Today, Claritas Genomics, Inc., announced the launch of its Claritas Clinical Exome, at the Annual Meeting of the American Society of Human Genetics running 10/6 – 10/10 in Baltimore, MD. This novel diagnostic test is the first to exploit the strengths of multiple DNA sequencing platforms simultaneously to deliver …

Read More »

Exelixis Announces Positive Results for its Late-Stage Melanoma Trial

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Oct. 6, 2015– Exelixis, Inc.(NASDAQ:EXEL) today announced positive overall survival (OS) results from coBRIM, the phase 3 pivotal trial evaluating cobimetinib, a specific MEK inhibitor discovered by Exelixis, in combination with vemurafenib in previously untreated patients with unresectable locally advanced or metastatic melanoma carrying a BRAF V600 …

Read More »

FDA Expands Approval of Merck’s Keytruda for Treatment of Advanced NSCLC

KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) monotherapy, the company’s anti-PD-1 (programmed death receptor-1) therapy, at a dose of 2 mg/kg every three weeks, for the treatment of patients with …

Read More »

FDA Approves AstraZeneca’s Iressa for First-Line Use in Patients with Lung Cancer

The U.S. Food and Drug Administration today approved Iressa (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor specific types of epidermal growth factor receptor (EGFR) gene mutations, as detected by an FDA-approved test. Lung cancer is the leading cause of cancer-related …

Read More »